Trials / Completed
CompletedNCT04439838
A Study in Healthy Men to Test How Different Doses of BI 1595043 Are Tolerated
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1595043 (Single-blind, Partially Randomised, Placebo-controlled, Parallel (Sequential) Group Design) in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1595043 in healthy male subjects following oral administration of single rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1595043 | BI 1595043 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2020-08-13
- Primary completion
- 2021-03-19
- Completion
- 2021-03-19
- First posted
- 2020-06-19
- Last updated
- 2024-02-21
- Results posted
- 2024-02-21
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT04439838. Inclusion in this directory is not an endorsement.